Vericel Corp
VCEL
NASDAQ
Biotechnology
$44.20
USD
-0.34 (-0.76%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $2.26B
Volume 276.1K
Revenue
$306.30M
TTM
+23.0%
YoY
Gross Margin
75%
TTM
+1.5%
YoY
Net Income
$24.22M
TTM
+240.8%
YoY
Operating Cash Flow
$69.67M
TTM
+47.5%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 63.2 | 67.5 | 92.9 | 68.4 | 77.5 |
YoY Growth | +20.1% | +16.6% | +23.3% | +30.1% | +22.5% |
Cost of Revenue | 16.6 | 17.9 | 19.8 | 19.2 | 21.1 |
Gross Profit | 46.6 | 49.6 | 73.1 | 49.3 | 56.4 |
Selling, General & Administrative | 41.9 | 39.8 | 43.5 | 49.2 | 48.5 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 48.6 | 46.1 | 50.7 | 57.3 | 56.0 |
Operating Income | -2.0 | 3.5 | 22.4 | -8.1 | 0.4 |
EBITDA | 0.8 | 6.4 | 25.5 | -4.8 | 4.1 |
Other Income / Expense | -0.0 | -0.0 | -0.0 | 0.1 | -0.0 |
Total Other Income / Expense | 1.5 | 1.6 | 1.7 | 1.8 | 1.8 |
Income Before Income Taxes | -0.6 | 5.1 | 24.1 | -6.3 | 2.2 |
Income Taxes | 0.0 | 0.0 | 0.9 | 0.0 | 0.0 |
Net Income | -0.6 | 5.1 | 23.2 | -6.3 | 2.2 |
Consolidated Net Income / Loss | -0.6 | 5.1 | 23.2 | -6.3 | 2.2 |
Net Income Attributable to Common Shareholders | -0.6 | 5.1 | 23.2 | -6.3 | 2.2 |
Basic EPS | -$0.01 | $0.10 | $0.46 | -$0.12 | $0.04 |
Diluted EPS | -$0.01 | $0.10 | $0.41 | -$0.12 | $0.04 |
Basic Shares Outstanding | 50.4M | 50.5M | 50.6M | 50.8M | 51.1M |
Diluted Shares Outstanding | 50.4M | 51.9M | 56.4M | 50.8M | 52.3M |